Survival Methods-Reference-Cited by-同舟云学术

Survival Methods

Published:2007-01-02 Issue:1 Volume:115 Page:109-113
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Rao Sowmya R.¹,Schoenfeld David A.¹

Affiliation:

1. From Massachusetts General Hospital Biostatistics Center and Institute for Health Policy (S.R.R.), and Massachusetts General Hospital Biostatistics Center, Department of Biostatistics, Harvard School of Public Health (D.A.S.), Boston, Mass.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.106.614859

Reference21 articles.

1. Estimation of the failure time distribution in the presence of informative censoring

2. Nonparametric Estimation from Incomplete Observations

3. Sample-Size Formula for the Proportional-Hazards Regression Model

4. Schoenfeld DA. Find statistical considerations for a study where the outcome is a time to failure. Available at: http://biostatistics.mgh.harvard.edu/sample_size/quan_measur/para_time.html. 2001. Accessed December 13 2006.

5. Kalbfleisch JD Prentice RL. The Statistical Analysis of Failure Time Data. New York NY: Wiley; 1980.

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of 30-day antecedent antibiotic exposure on Clostridioides difficile ribotype patterns and the relationship with clinical outcomes: A single center study;Anaerobe;2024-10

2. The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience;The Journal of Infectious Diseases;2024-05-23

3. Advanced considerations in survival analysis;European Journal of Cardio-Thoracic Surgery;2024-01-19

4. Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study;Open Forum Infectious Diseases;2023-12-08

5. Dealing With Nonproportional Hazards in Coronary Revascularisation Studies;Canadian Journal of Cardiology;2023-07